article thumbnail

‘Ice Bucket Challenge’ funds FDA-approved ALS treatment

Drug Discovery World

In June 2016, the Association provided Amylyx, the producer of AMX0035, with a $750,000 grant for a clinical trial pilot. Then in July 2016, the Association provided the Northeast ALS Consortium (NEALS) with a $1.46 The post ‘Ice Bucket Challenge’ funds FDA-approved ALS treatment appeared first on Drug Discovery World (DDW).

article thumbnail

Metabolism of 2023 FDA Approved Small Molecules – PART 1

Metabolite Tales Blog

Metabolism of 2023 FDA Approved Small Molecules – PART 1 By Julia Shanu-Wilson 2023 was a fruitful year for drug approvals by the FDA, with a crop of 34 small molecules out of a total of 55 new drugs [1]. link] [3] FDA prescribing information for daprodustat. Basic Clin Pharmacol Toxicol. 131(5): 311- 324.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Lower-Profile Web Intrasaccular Aneurysm Treatment Device Receives FDA Approval

The Pharma Data

based subsidiary of Terumo and a global neurovascular company, announced today the FDA Approval of the PMA Supplement for the WEB 17 System, a new addition to the WEB Aneurysm Embolization System for the treatment of intracranial wide neck bifurcation aneurysms. . ALISO VIEJO, Calif. ,

article thumbnail

Joint Basis for FDA/HHS Marijuana Rescheduling Recommendation Unveiled

FDA Law Blog: Biosimilars

FDA conducted the eight-factor scheduling analysis required by the CSA in 2016 and found that marijuana continued to meet the scheduling criteria for remaining in schedule I. 12, 2016); Denial of Petition to Initiate Proceedings to Reschedule Marijuana, 81 Fed. 53,688 (Aug. 53,767 (Aug. 21 U.S.C. § at 53,700; 81 Fed.

FDA 69
article thumbnail

HHS’ Recommendation to Reschedule Cannabis to Schedule III Raises Questions

FDA Law Blog: Biosimilars

DEA and HHS last considered rescheduling cannabis in 2016. 12, 2016); Denial of Petition to Initiate Proceedings to Reschedule Marijuana, 81 Fed. 12, 2016); Denial of Petition to Initiate Proceedings to Reschedule Marijuana, 81 Fed. The 2016 review concluding that cannabis remain in schedule I was dependent on several factors.

FDA 111
article thumbnail

FDA Approves Myovant Drug as First-Ever Oral Hormone Therapy for Prostate Cancer

The Pharma Data

Myovant was launched in 2016 as one of Vivek Ramaswamy’s family of biotech Vants after a deal with Takeda for a prostate cancer drug and a female infertility drug. However, Myovant’s drug dropped the percentage of major cardiovascular events to 2.9% compared to AbbVie’s at 6.2%.

article thumbnail

DEA Concurs: Marijuana Meets Schedule III Criteria

FDA Law Blog: Biosimilars

FDA/HHS Analysis, 2023 FDA/HHS last conducted an eight-factor analysis of marijuana in 2016 and concluded that marijuana continued to meet schedule I criteria. 12, 2016); Denial of Petition to Initiate Proceedings to Reschedule Marijuana, 81 Fed. Denial of Petition to Initiate Proceedings to Reschedule Marijuana, 81 Fed.

FDA 95